RARA CRAFT DATABASE for FDA Medical Devices
510(k)K212216

FDA DEVICE FACTS

Prismaflex ST60 Set, Prismaflex ST100 Set, Prismaflex ST150 set

Baxter Healthcare Corporation

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEApril 1, 2022PRODUCT CODEKDI

Indications for use

The Prismaflex ST set is a single use device that provides blood purification through a semipermeable membrane. The Prismaflex ST set is for use only in conjunction with the PrismaFlex control unit or with the PrisMax control unit (in countries where PrisMax is cleared or registered). All treatments administered via the PrismaFlex ST sets must be prescribed by a physician. The size, weight, state of uremia, cardiac status, and general physical ' K212216 condition of the patient must be carefully evaluated by the prescribing physician before each treatment. If patients suffer from acute kidney injury and / or volume overload, the Prismaflex ST set is indicated for continuous renal replacement therapies (CRRT), in modalities such as:

• Slow Continuous UltraFiltration (SCUF)

• Continuous Veno-Venous Hemofiltration (CVVH)

• Continuous Veno-Venous HemoDialysis (CVVHD)

• Continuous Veno-Venous HemoDiaFiltration (CVVHDF) to perform fluid management and reduction of uremic toxins. The Prismaflex ST100 and ST150 set is indicated for use in patients with a body weight equal or greater than 30 kg (66lb) and Prismaflex ST60 set is indicated to patients with a body weight greater than 11kg (24lb). TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE: The Prismaflex ST set has the same intended use and the same technological characteristics compared to its predicate, the Prismaflex M set, in term of design, material, chemical composition, function and operation. The safety and performance of Prismaflex ST set was evaluated through non-clinical testing. The bench and pre-clinical testing assessed the following aspects of the device:

• Structural integrity

• Membrane integrity

• Ultrafiltration rate

• Clearances

• Sieving coefficients

• Blood pressure drop

• Total volume of blood in the set

• Priming efficacy

• Shelf life

• Sterilization validation '

• Pyrogenicity / LAL

• EO residuals

• Biocompatibility DISCUSSION OF NONCLINICAL TESTS:

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 23, 2026